Patents by Inventor Ian Robert Lynch

Ian Robert Lynch has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Substituted thiazolidinedione derivative, process for its preparation and its pharmaceutical use
    Patent number: 7368574
    Abstract: A hydrate of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, maleic acid salt., characterized in that it: (i) comprises water in the range of from 0.3 to 0.6 molar equivalents; and (ii) provides an infra red spectrum containing peaks at 1757, 1331, 1290, 1211 and 767 cm?1; and/or (iii) provides a Raman spectrum containing peaks at 1758, 1610, 1394, 1316 and 1289 cm?1; and/or (iv) provides a solid state nuclear magnetic resonance spectrum containing chemical shifts substantially as set out in Table I herein; and/or (v) provides an X-ray powder diffraction (XRPD) pattern substantially as set out in FIG. IV herein; a process for the preparation of such a compound, a pharmaceutical composition containing such a compound and the use of such a compound or composition in medicine.
    Type: Grant
    Filed: September 28, 2006
    Date of Patent: May 6, 2008
    Assignee: SmithKline Beecham p.l.c.
    Inventors: Ian Robert Lynch, Michael John Sasse, Bernadette Marie Choudary
  • Substituted thiazolidinedione derivative, process for its preparation and its pharmaceutical use
    Publication number: 20030139604
    Abstract: A hydrate of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, maleic acid salt, characterised in that it: (i) comprises water in the range of from 0.3 to 0.6 molar equivalents; and (ii) provides an infra red spectrum containing peaks at 1757, 1331, 1290, 1211 and 767 cm−1; and/or (iii) provides a Raman spectrum containing peaks at 1758, 1610, 1394, 1316 and 1289 cm−1; and/or (iv) provides a solid state nuclear magnetic resonance spectrum containing chemical shifts substantially as set out in Table I herein; and/or (v) provides an X-ray powder diffraction (XRPD) pattern substantially as set out in Figure IV herein; a process for the preparation of such a compound, a pharmaceutial composition containing such a compound and the use of such a compound or composition in medicine.
    Type: Application
    Filed: January 30, 2003
    Publication date: July 24, 2003
    Applicant: SmithKline Beecham p.l.c.
    Inventors: Ian Robert Lynch, Michael John Sasse, Bernadette Marie Choudary
  • Polymorphic forms of cipamfylline
    Patent number: 6583283
    Abstract: This invention relates to novel crystalline polymorphic forms, Form I, II and IV of Cipamfylline, methods of preparation, and use thereof in the treatment of PDE4 and TNF mediated diseases.
    Type: Grant
    Filed: August 15, 2000
    Date of Patent: June 24, 2003
    Assignee: SmithKline Beecham Corporation
    Inventors: Drake S Eggleston, Ian Robert Lynch
  • Novel polymorphic forms of cipamfylline
    Publication number: 20020173648
    Abstract: This invention relates to novel crystalline H polymorphic forms, Form I, II and IV of Cipamfylline, methods of preparation, and use thereof in the treatment of PDE4 and TNF mediated diseases. Cipamfylline is 1,3-di-cyclopropylmethyl-8-amino xanthine, and represented by formula (I).
    Type: Application
    Filed: April 18, 2002
    Publication date: November 21, 2002
    Applicant: SmithKline Beecham Corporation
    Inventors: Drake S. Eggleston, Ian Robert Lynch
  • Substituted thiazolidined derivative, process for its preparation and its pharmaceutical use
    Publication number: 20020133016
    Abstract: A hydrate of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl)thiazolidine-2,4-dione, maleic acid salt, characterized in that it: (i) comprises water in the range of from 0.3 to 0.6 molar equivalents; and (ii) provides an infra red spectrum containing peaks at 1757, 1331, 1290, 1211 and 767 cm−1; and/or (iii) provides a Raman spectrum containing peaks at 1758, 1610, 1394, 1316 and 1289 cm−1; and/or (iv) provides a solid state nuclear magnetic resonance spectrum containing chemical shifts substantially as set out in Table I herein; and/or (v) provides an X-ray powder diffraction (XRPD) pattern substantially as set out in FIG. IV herein; a process for the preparation of such a compound, a pharmaceutical composition containing such a compound and the use of such a compound or composition in medicine.
    Type: Application
    Filed: February 8, 2002
    Publication date: September 19, 2002
    Applicant: SmithKline Beecham p.l.c.
    Inventors: Ian Robert Lynch, Michael John Sasse, Bernadette Marie Choudary